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ABSTRACT 
FIXATION OF COMPLEMENT BY ANTI-F(ab')2 ANTIBODIES OR ssDNA 
WHEN ADDED TO SYSTEMIC LUPUS ERYTHEMATOSUS SERA 
David Allen Shrier 
1984 
Recently, it has been demonstrated that anti-F(ab')2 
antibodies directed against the F(ab1 ) 2 portions of 
immunoglobulins are present in the sera of patients with 
rheumatic diseases. The in vitro complement fixing activity 
of these anti-F(ab')2 antibodies, when directed against 
F(ab')2 portions of immunoglobulins, is unknown. In this 
study, a solid phase total hemolytic complement assay was 
used to quantitatively determine the % complement fixation 
by anti-F(ab')2 antibodies or ssDNA when added to serum from 
patients with systemic lupus erythematosus (SLE). Both 
autologous and homologous anti-F(ab')2 antibodies with 
demonstrated anti-anti-ssDNA activity fixed complement when 
added to SLE sera and normal human complement. Furthermore, 
comparable amounts of anti-F(ab')2 antibodies with minimal 
anti-anti-ssDNA activity fixed zero or minimal amounts of 
complement when added to the same lupus sera. ssDNA, when 
measured by the same assay with the same sera, fixed greater 
amounts of complement than did comparable amounts of any of 
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The immune system 
It is difficult to conceive of a mechanism more lethal 
than the human immune response. It possesses the ability to 
identify and respond rapidly to foreign elements with 
exquisite specificity and potent effector mechanisms. These 
events are the result of a complex network of signals and 
interactions by a number of different cells which together 
provide "homeostasis" (1). This network is provided with 
checks and balances via regulatory cells (helpers or 
suppressors) acting at both the T-T and T-B cell level. One 
of the functions of this regulatory system is to govern the 
specificity and magnitude of the antibody response to 
foreign proteins. 
The immune system was originally conceived of as a 
defense mechanism against only infectious agents. However, 
at the turn of the century, Ehrlich coined the phrase 
"horror autotoxicus" to describe the idea that the body 
might rebel against itself. He postulated the existence of 
strict "internal regulating contrivances" to prevent this 
type of rebellion (2). Indeed, we now know that one of the 
consequences of a malfunction of such a regulatory system is 




Burnet as "A condition in which structural or functional 
damage is produced by the action of immunologically 
competent cells or antibody (directed) against normal 
components of the body." (3). 
The reality of such self-destructiveness first became 
apparent with the description of autoimmune hemolytic anemia 
and from multiple experiments demonstrating that proper 
immunization could induce animals to form autoantibodies. 
These autoantibodies were postulated by Burnet, in his 
clonal selection theory, to be products of "forbidden 
clones" that were potentially self-reactive and had somehow 
escaped destruction (4). However, as clinical and 
experimental evidence of autoantibodies and autoimmune 
phenomena accumulated it became clear that autoreactive 
cells were normally present in animals and humans (2, 5). 
Thus, far from being a forbidden event, self-recognition now 
appears to be a basic principle of the immune system. 
In 1974 N.K. Jerne (6) first advanced the network theory 
of the immune system which proposes that immunologic control 
is mediated by a complex network of anti-idiotype 
antibodies. These antibodies are directed against unique 
antigens (idiotypes) created by the individual combining 
sites of antibodies. Idiotypes are also present on antigen 
recognition molecules on the surface of B and T lymphocytes 
and, under experimental conditions, anti-idiotypic 
antibodies can either stimulate or suppress the function of 
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those lymphocytes bearing the appropriate idiotypic 
antigens. Additionally, it has been shown that recognition 
of the antigens of the major histocompatibility complex is 
also important in cooperation between lymphocytes or 
lymphocytes and macrophages. Thus, the immune system 
appears to be an intricate network of signals and receptors 
in constant communication and perpetual readjustment through 
negative and positive feedback mechanisms to self and non¬ 
self antigens. The concept of self-recognition has evolved 
from "never" (ie. forbidden clones) to "always with control" 
(2). 
Autoimmunity 
Autoimmune diseases, therefore, are most likely a result 
of defective immunoregulation. One widely accepted theory 
maintains that self-reactive B cells which are always 
present normally remain dormant because of suppressor T cell 
control or because helper T cells capable of recognizing 
autoantigens are absent or inactive. Loss of control with 
subsequent hyperactivity of B cells may result from a 
decreased number of suppressor T cells or a defect in 
suppressor cell function secondary to either a primary 
defect or to autoantibody directed against their cellular 
surface (1, 4, 8, 9, 10). Control may also be bypassed if 
foreign antigens and self antigens are linked together so 
that the T cell recognizing the foreign part of the antigen 
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can help the B cell recognizing the self part of the same 
antigen complex. Such a process may occur after a foreign 
antigen such as a drug adheres to a cell's surface or after 
viral antigens appear on the surface of a virus infected 
cell. The result would be production of antibody to self 
antigens on the cell surface. Similarly, formation of 
antibodies (rheumatoid factors) against other antibodies 
linked to foreign antigens in an immune complex or 
nonspecific stimulation of B cells by adjuvants might also 
bypass the helper T lymphocyte gap. 
Other postulated mechanisms for deregulation include a 
genetic defect or viral infection specific for helper or 
suppressor T cells that would decrease the effectiveness of 
that cell leading to an imbalance in the system. Imbalance 
might also occur secondary to a genetic defect rendering B 
cells incapable of producing antibody upon proper 
stimulation. This might lead to overreaction in another 
part of the immune system in addition to failure of the 
effector function of the antibody. 
Immunopathology and SLE 
The concept that immunologic injury to specific organs or 
tissues might occur as a result of antigen-antibody 
reactions immunologically unrelated to the structures 
injured was first voiced by Von Pirquet as early as seventy 
years ago (11). In the course of studying serum sickness in 
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humans he postulated that the coexistence of foreign serum 
antigens and homologous antibodies in the circulation 
resulted in the formation of toxic compounds which were 
probably the cause of rather specific vascular, renal, 
cardiac, cutaneous and joint lesions developing in tissues 
without immunologic relationship to the injected antigen. 
It was not until almost fifty years later that it was firmly 
established that antigen-antibody complexes per se are 
pathogenetic agents capable of inducing a variety of 
injuries, ranging from acute through chronic inflammation to 
hyaline degeneration in particular anatomic sites. 
This concept of immunologically induced tissue injury was 
first applied to systemic lupus erythematosus (SLE), 
particularly to lupus nephritis, in 1948 when M.M. Hargraves 
et. al. first noted the lupus erythematosus (LE) cell 
phenomenon in the bone marrow of patients with SLE (12). 
Approximately ten years later the immunologic nature of the 
LE cell phenomenon, observed in approximately 75% of lupus 
patients, was established when gamma globulin (7S IgG) with 
specificity for deoxyribonucleoprotein was identified as the 
reactive serum fraction involved. In the years that 
followed further serologic studies of SLE have revealed that 
the disease is characterized by a generalized excessive 
autoantibody production. These autoantibodies are 
postulated to be produced by excessive B cell activity 
arising from a defect in suppressor T cells. Though the 
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exact mechanism for this is unknown, it is most likely the 
result of anti-lymphocyte antibodies acting on discrete 
subsets of T cells rather than a primary cellular defect (1, 
4). It is these autoantibodies that then go on to form 
immune complexes with self antigens and in this way 
participate in the pathogenesis of SLE. 
Autoantibodies in SLE 
The work of many investigators has delineated a great 
number of different autoantibodies that may appear in the 
serum of SLE patients (10, 12). Among those currently 
recognized are antibodies directed against nuclear 
constituents (double-stranded DNA (dsDNA), single-stranded 
DNA (ssDNA), deoxyribonucleoprotein, ribonucleoprotein, Sm 
antigen, and carbohydrate antigens), cytoplasmic 
constituents (ribosomes, carbohydrate antigens, lipid 
antigens), gamma globulin, soluble clotting factors, 
platelets, red blood cells, lymphocytes and double or 
single-stranded RNA. Some of this antibody activity may be 
seen in other diseases whereas some is relatively specific 
for SLE. For example, anti-deoxyribonucleoprotein activity 
(the LE cell phenomenon) occurs in approximately 15% of 
patients with other rheumatic diseases. Anti-ssDNA is also 
found in patients with rheumatoid arthritis (RA), chronic 
active hepatitis, primary biliary cirrhosis, Sjogren's 
syndrome and drug-induced lupus-like syndromes. On the 
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other hand, high titers of anti-dsDNA are seen essentially 
only in SLE (found in 40% of SLE patients) although low 
concentrations are present in other rheumatic diseases 
(12-15). 
Antibodies to dsDNA were among the first to be described 
in lupus patients. Aside from their usefulness in 
diagnosis, measurements of anti-dsDNA antibodies are useful 
in monitoring patients, because of the close correlation of 
increased titers with clinical exacerbation. SLE patients 
with these antibodies have a high incidence of clinical 
renal disease and serum hypocomplementemia. Studies of SLE 
patients dying with renal disease have shown increased 
concentrations of anti-dsDNA antibodies in their kidneys 
compared to serum. These data strongly suggest a pathologic 
role for dsDNA-anti-dsDNA immune complexes in the genesis of 
glomerulonephritis in these patients (13, 15). 
Antibodies to ssDNA probably also play a major role in 
the immunopathogenesis of SLE. They are found in the great 
majority of SLE patients (70-75%) though they are non¬ 
specific. As with anti-dsDNA, anti-ssDNA antibodies have 
been eluted in increased concentrations from the kidneys 
(compared to serum) of some SLE patients dying with 
glomerulonephritis. There has also been described a group 
of patients with prominent cutaneous lesions and severe 
renal disease who have anti-ssDNA antibodies but have 
repeatedly failed to demonstrate anti-nuclear and anti-dsDNA 
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antibodies. These data suggest that immune complexes 
composed of ssDNA-anti-ssDNA also play a pathologic role in 
glomerulonephritis in SLE patients (13, 15). 
Immune complexes and hypocomplementemia 
We opened this discussion of the immunopathologic basis 
of SLE with the concept of immune complex mediated tissue 
injury. In the past ten to fifteen years a large number of 
methods for detecting immune complexes have been developed 
including Clq-binding assays, polyethylene glycol (PEG) 
precipitation assays and Raji cell binding assays. All of 
these show marked elevations of circulating immune complexes 
(CIC's) in SLE sera during acute episodes of the disease 
(12). In addition, immune complex deposition is closely 
correlated with histologic evidence of inflammatory lesions 
and dysfunction of renal glomeruli, renal tubules, blood 
vessels, synovial tissues, pleural and pericardial 
membranes, and alveolar septae of the lung. On the other 
hand, cytotoxic antibodies which directly interact with in 
situ membrane antigens (eg. anti-red blood cell antibodies) 
play a more limited role in the pathogenesis of SLE. The 
localization and potential cytotoxicity of circulating 
and/or locally formed antigen-antibody complexes is 
determined by multiple factors. The molecular size of the 
complex, the antigen-antibody ratio, the ability to fix 
complement, the avidity of the antibody component, the ionic 
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charge of the complex and the clearance of CIC's by the 
reticuloendothelial system have all been implicated as 
determinants of the pathogenicity of immune complexes (8). 
However, activation of the classical complement pathway 
appears to be a prerequisite for the expression of immune 
complex mediated tissue injury (8, 15). In fact, 
hypocomplementemia is one of the prominent humoral 
immunologic abnormalities in patients with active SLE (10, 
16) . 
Hypocomplementemia may result from increased utilization 
(eg. as a result of immune complex formation), reduced 
synthesis or a combination of the two. In SLE the mechanism 
of increased utilization is indicated by a number of 
findings. These include significant depression of early 
complement components in hypocomplementemic SLE sera, 
identification of early complement components in renal 
lesions and the complement fixing ability of anti-DNA 
antibodies when added to DNA in vitro using a liquid phase 
total hemolytic complement assay (12, 17, 18). Studies have 
also revealed that fixation of complement occurs via both 
the classical and alternative pathways of complement 
activation, though the former is more actively utilized. 
Regardless of which pathway is activated it has been clearly 
demonstrated that the complement fixing activity of DNA- 
anti-DNA complexes is directly associated with the presence 
of active lupus nephritis (12, 15, 19, 20). There is also 
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evidence that a variety of other immune complex systems 
participate in complement fixation and disease activity 
(12). However, the precise mechanism by which complement 
proteins participate in the inflammatory response in SLE in 
vivo remains to be clarified (8). 
Anti-idiotypic antibodies and the network theory 
We mentioned earlier that, in 1974, N.K. Jerne first 
advanced the network theory of the immune system in which 
anti-idiotypic antibodies play a regulatory role (6). 
Specifically, he suggested that the normal immune response 
not only includes production of specific antibody (Abl) to a 
given antigen but that the resulting antibody can itself act 
as an antigen for the induction of a second anti-idiotypic 
antibody (Ab2). Amino acids of the hypervariable regions of 
the Abl molecule associated with the antigen combining site 
and a portion of the surrounding framework region make up 
the antigen structure of the idiotype (7). These amino acid 
sequences are all contained within the F(ab')2 portion of 
the immunoglobulin (2). The anti-idiotypic antibody (Ab2) 
reacts with this antigenic structure and is therefore 
referred to as anti-F(ab' ) 2 antibody. In turn, the 
antigenic structure of the Ab2 molecule can also serve as an 




The existence of such a regulatory network has been 
confirmed in animal models and in man by the work of many 
investigators (5, 21-23). We now know that this regulatory 
system is complicated and involves interactions between T 
and B cells bearing the target idiotypes or anti-idiotypes 
as well as interactions between those cells and circulating 
anti-idiotypic or anti-anti-idiotypic antibodies. In some 
systems, anti-idiotypes can suppress idiotype expression 
whereas in others they have been shown to enhance expression 
of idiotype (21-23). Of note is that although the above 
conclusions are based on experimental systems in which anti- 
idiotypic antibodies have been administered before or during 
the course of an immune response, there is also evidence 
that idiotypic regulation occurs during the normal immune 
response (21). 
Complement fixing ability of anti-F(ab1)? antibodies 
It has recently been demonstrated that anti-F(ab' ) 2 
(auto-anti-idiotypic) antibodies directed against the 
F(ab')2 portions of immunoglobulins are present in the sera 
of patients with rheumatic diseases or IgA deficiencies as 
well as in normals (5, 24-27). These anti-F(ab')2 
antibodies in patients with SLE have been shown to include 
cross-reacting antibodies with specificity for anti-DNA 
(idiotype) and are believed to have a role in the regulation 
of the immune response in accordance with Jerne's network 
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theory (5-6, 23, 25, 28). In vivo studies have suggested 
that, in lupus patients, high titers of anti-F(ab')2 
antibodies are associated with low titers of anti-DNA and 
low levels of disease activity (5). This has been taken one 
step further by Hahn and colleagues (28) who have 
demonstrated that, in NZB/NZW mice, survival was 
significantly prolonged in those mice treated with anti¬ 
idiotype (anti-anti-DNA) and antibodies to DNA were 
transiently diminished in quantity versus those mice not 
similarly treated. However, it has also recently been 
demonstrated by Lambert and colleagues (29-30) that BALB/c 
mice immunized with lipopolysaccharide (LPS) or infected 
with trypanosomes exhibited idiotype-anti-idiotype CIC's. 
This group then went on to show that these same immune 
complexes are deposited in glomerular lesions in BALB/c mice 
injected with LPS and may well be pathogenic (31). 
As pointed out previously the complement activity of 
anti-DNA has been directly associated with the presence of 
active lupus nephritis in humans and anti-DNA antibodies are 
known to be complement fixing when added to DNA in vitro. 
The complement fixing activity of anti-F(ab')2 antibodies in 
patients with SLE has not been studied, but has obvious 
clinical significance given the preceding considerations. 
Thus, in this study we have tested the complement fixing 
activities of ssDNA and anti-F(ab')2 antibodies when added 
to SLE sera with various anti-ssDNA antibody activities. 
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Using a solid phase sensitized sheep red blood cell total 
complement assay (Kallestad, Chaska, Minn.) we have shown 
that autologous and homologous anti-F(ab')2 antibodies, with 
known anti-anti-ssDNA activity, fixed complement when added 
to SLE sera. 
However, relatively greater quantities of complement were 
fixed when comparable amounts of ssDNA were added to the 
same sera. In both the ssDNA and anti-F(ab')2 complement 
fixation assays there was a tendency for the higher ssDNA 
binding sera to fix greater amounts of complement than the 
lower ssDNA binding sera. Furthermore, anti-F(ab')2 
antibodies with minimal anti-anti-ssDNA activity fixed 
little or no complement when added to the same SLE sera. 

MATERIALS AND METHODS 
Patients and sera 
Sera were obtained by venipuncture from informed patients 
at the UCLA Center for the Health Sciences and from normal 
volunteers. The patients with systemic lupus erythematosus 
(SLE) fulfilled the American Rheumatism Association criteria 
for classification of SLE (32) and the patients with 
rheumatoid arthritis (RA) fulfilled criteria for "Definite" 
or "Classical" RA (33). All samples were frozen at -20°C 
until use. 
Single-stranded DNA was prepared by heating preparations 
of calf thymus DNA (Sigma Chem. Co., St. Louis, Mo.) at 
100°C for 10 mins, and then rapidly cooling in an ice bath. 
Immunoglobulin and its fragments 
Human IgG was prepared from Cohn Fraction II (Miles Lab, 
Elkhart, Ind.) by elution from DEAE-cellulose column 
chromatography with 0.01 M potassium phosphate buffer, pH 
8.0. F(ab')2 fragments were prepared by pepsin digestion of 
IgG (24, 34). The F(ab')2 was separated by collecting the 
excluded peak from a Sephadex G-75 column and subjecting 
this to two successive purifications using Sephadex G-200 to 




fragments. This F(ab') 2 preparation was free of Fc 
fragments and undigested IgG by Ouchterlony analysis against 
specific rabbit anti-human Fc antiserum (Behring, 
Somerville, N.J.) at concentrations of up to 24 mg/ml and 
shown to have a purity greater than 98%. Concentrations of 
1 gm/dl of this F(ab1)2 preparation bound 8% ssDNA in the 
Farr assay (see below). 
Purification of specific antibodies by affinity column 
chromatography 
Anti-F(ab')2 antibodies were purified from the sera of 
patients with SLE and RA by affinity column chromatography 
using F(ab')2 conjugated to Sepharose 4B (Pharmacia, 
Uppsala, Sweden). The immunoabsorbent contained 
approximately 5 mg of F(ab’)2/ml of gel. Antibodies were 
eluted from the column by lowering the pH of the column to 
3.5 in 0.1 M glycine, 1.5 M NaCl. These anti-F(ab')2 
antibody preparations were concentrated to l/10th of the 
original serum volume by ultrafiltration, to a final protein 
concentration of approximately 300-600 ug/ml. 
Anti-Fc antibodies (19S) were purified from the serum of 
an RA patient. The serum v/as first precipitated with 50% 
saturated ammonium sulfate. The precipitant was passed 
through two successive columns of IgG coupled to Sepharose 
4B and the eluted XgM fraction was then purified by 
exclusion from a Sephadex G200 column. Any contaminating 
anti-F(ab')2 antibodies were then removed from the anti-Fc 
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antibodies by exclusion chromatography from an F(ab' ) 2 
Sepharose 4B column. The excluded effluents of IgM anti-Fc 
antibodies (19S) had anti-IgG titers of 80,000 or greater 
and negative anti-F(ab')2 titers by radioimmunoassay (RIA) 
as described below. IgM (19S) anti-Fc antibodies (anti-IgG 
titers of 800) were used to enhance the reaction of anti- 
F(ab' )2 antibodies with 1251-aggregated F(ab')2 (35). 
Radioimmunosassay for anti-IgG and anti-F(ab1)2 antibodies 
The radioimmunoassay for anti-IgG and anti-F(ab')2 was 
done in the manner previously described (24-25). IgG and 
F(ab')2 fragments were radiolabeled with 125I (Amersham 
Corp., Arlington Heights, Ill.) to a specific activity of 
0.1 mCi/mg by the chloramine-T method (36). Aggregations 
were performed by heating 10 mg/ml of labeled proteins for 
30 mins, at 63°C for IgG and 60°C for 20 mins, for F(ab')2. 
Aggregates of IgG (A-IgG) and F(ab')2 (A-Fab) with molecular 
weights of approximately lxlO7 daltons were separated by 
sucrose density gradient (10-30%) ultracentrifugation at 
180,000 g for 4 hrs. with a Beckman Sw40 rotor (Beckman, 
Palo Alto, Cal.) at 4°C (37). 
Fifty microliters of purified anti-F(ab')2 or anti-IgG 
antibodies were twofold serially diluted with 0.01 M sodium 
phosphate-buffered saline, pH 7.4 (PBS), containing 0.05% 
NaN3 and 0.5% bovine serum albumin (BSA) in a microtiter 
plate (Dynatech., Alexandria, Va.). Then 100 ul of PBS 

17 
containing 0.5% BSA was added to each well and heat- 
inactivated at 56°C for 30 mins. Fifty microliters of each 
diluted sample were transferred to two different microtiter 
plates. A-IgG or A-Fab (0.025 ug in 25 ul) were added to 
each well, followed by 50 ul of 3% polyethylene glycol (3% 
PEG-6000), 0.02 M EDTA, and approximately 10,000 cpm of 22Na 
(Amersham) as a volume marker. The wells containing A-Fab 
also received 25 ul of purified IgM-19S-anti-Fc antibodies 
while the wells containing A-IgG received 25 ul PBS. The 
plates were then agitated and incubated at room temperature 
for 16 hrs. The plates were centrifuged at 2000 g for 40 
mins., the supernatants were aspirated and the pellets were 
counted for 12 51 and 2 2Na activities in a dual-channel 
automated gamma counter (Beckman). The titer of anti-IgG 
was defined as that dilution which precipitated 33% of the 
antigen whereas the percent binding for a given 
concentration of anti-F(ab')2 was calculated as [(125I in 
precipitate)/(1251 in 25 ng of A-Fab)] x 100%. 
Radioimmunoassay for anti-ssDNA antibodies and the 
inhibition assays 
Anti-ssDNA antibody activities were determined by a 
modified Farr test as described previously (38). Briefly, 
10 ul of serum and 80 ul of borate saline containing 0.5% 
BSA and approximately 10,000 cpm of 22Na, as a volume 
marker, were mixed and heat inactivated. Ten microliters of 
12 51-ssDNA (0.034 ug) was added and incubated at 37°C and 
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4°C for 1 and 16 hrs., respectively. Then 100 ul of 
saturated ammonium sulfate was added and incubated at 4°C 
for 30 mins, and centrifuged at 1000 g for 30 mins. The 
supernatants were decanted and the pellets were counted for 
125I and 22Na activities. The percentage DNA binding was 
calculated as [(125I in precipitate)/(1251 in 10 ul of 125I- 
ssDNA)] x 100%. 
For the inhibition tests, the Farr test was slightly 
modified. Five microliters of serum and 80 ul of borate 
buffered saline containing 0.5% BSA and 2 2Na were mixed and 
heat inactivated. Five microliters of inhibitor was added 
and incubated at 37°C and 4°C for 1 hr. each. Then 10 ul of 
12 51-ssDNA was added, and the assay was carried out in the 
same manner as for anti-ssDNA antibodies. The percent 
inhibition was determined by [((%binding with PBS) - (% 
binding with inhibitor))/(% binding with PBS)] x 100%. 
Complement fixation 
Levels of complement fixation were assayed using 
Kallestad Quantiplate total complement test kits (Kallestad, 
Chaska, Minn.). Each plate within a kit contained sheep red 
blood cells sensitized with hemolysin and standardized and 
immobilized in an agarose gel medium. The serum and/or 
mixture of reagents to be tested was placed in wells of 
equal dimensions and diffused radially through the agarose 
gel. The sheep red blood cells were lysed by complement to 
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form a cleared round zone. The total complement activity 
was measured by comparing the extent of lysis by the sample 
to that of reference sera using a semi-logarithmic graphical 
analysis. 
Preparation of the test reagents involved first adding 25 
ul of heat inactivated (56°C for 30 mins.) undiluted SLE 
serum to a test tube containing 25 ul of either ssDNA or 
purified anti-F(ab')2 antibody. Next 25 ul of human 
complement (approximately 30 CHX00 units) obtained from 
normal (circulating immune complex and anti-ssDNA negative) 
human sera (as determined by a polyethylene glycol 
precipitation assay (38) and by the modified Farr test (38), 
respectively) was added to the test preparation. For 
control values, equal amounts of PBS were substituted for 
the appropriate reagent(s). After mixing, the preparation 
was incubated for 1 hour at 37°C. Then 5 ul of the test 
preparation, along with 5 ul of the appropriate reference 
sera and controls were placed in the Quantiplate Test Kit 
wells and incubated for 6 hrs. at 37°C. The diameters of 
the cleared zones were read with a Kallestad viewer and the 
levels of the total hemolytic complement (in CHj00 units) 




Complement fixing ability of anti-F(ab1)2 antibodies in SLE 
sera 
Anti-F(ab')2 antibodies were purified by affinity column 
chromatography from SLE and RA patients' sera. Activities 
of the purified antibodies as measured by radioimmunoassay 
were shown to be positive (Table 1). Specificity of the 
purified anti-F(ab')2 antibodies for anti-ssDNA antibody was 
determined by their ability to inhibit the 12 51-ssDNA 
reaction with the anti-ssDNA. In our previous report (25) 
we demonstrated that purified anti-F(ab')2 antibodies from 
SLE sera inhibited the reactions between anti-ssDNA in sera 
with 12 51-ssDNA antigen; we also demonstrated that anti- 
F(ab')2 antibodies purified from RA sera did not inhibit 
these same reactions. In this study we used two of the same 
purified anti-F(ab')2 antibody preparations from the earlier 
study (RL and RI). In addition, we purified anti-F(ab')2 
antibodies from the serum of SLE patient DW. The percent 
inhibition of this purified anti-F(ab')2 antibody (DW) as 
defined under Methods was measured to be 44% using serum 
from patient MH (59% ssDNA binding); the prior study 
indicated that SLE serum RL had a mean percent inhibition of 




Thus, the anti-F(ab') 2 antibodies purified from SLE sera 
contain antibodies with greater specificity for anti-ssDNA 
antibodies than those anti-F(ab')2 antibodies purified from 
the RA serum. 
The ability of purified anti-F(ab')2 antibodies to fix 
complement when added to SLE serum was determined using the 
solid phase total hemolytic complement assay as described 
under Methods. The results of this assay are presented in 
Figure 1. The amount of complement fixed is given in terms 
of percent complement fixed. This is defined as 
[((complement activity present in complement source + serum 
+ PBS) - (complement activity present in complement source + 
serum + anti-F(ab')2))/(complement activity present in 
complement source + serum + PBS)] x 100%. The control serum 
(PC) was obtained from a normal human volunteer with a 
negative DNA binding test (< 20% binding). Also, controls 
were run in which high concentrations (_> 300 ug/ml) of anti- 
F(ab')2 antibodies purified from SLE or RA serum were added 
to the complement source without the addition of SLE serum. 
In none of these control runs was more than 15% of the total 
complement activity fixed. 
The anti-F(ab')2 antibody purified from SLE serum fixed 
complement when combined with either autologous (DW) or 
homologous (AS, MH, DH, BJ, PS) SLE serum (Figure 1A). 
Maximum complement fixation occurs at high concentrations of 
anti-F(ab')2 antibodies and decreases or remains steady as 




Purified Anti-F(ab' ) 2 Antibody Activities as Measured by 





purification & concentration) 
Percent Binding 
of 25 ng A-Fab* 
Anti-F(ab')2 
from SLE Patients 
RL 200 90 
DW 500 61 
Anti-F(ab1)2 
from RA Patient 
RI 30 33 
Note: RL and DW represent individual SLE patient donors. 
RI represents an individual RA patient donor. 
* These values can not be used for comparison since the 
concentrations of anti-F(ab' ) 2 antibodies differ 
greatly. The values are provided only to indicate that the 




A The percent complement fixation of various SLE sera or 
a normal control serum when added to various 
concentrations of anti-F(ab')2 antibody purified 
from SLE serum DW. 
a. ...Figures in parentheses indicate anti-ssDNA 
antibody activity (% binding to 34 ng of 
125I-ssDNA) of the various sera. 
b. ...Serum DW is autologous to the anti-F(ab')2 
antibody. 
B The percent complement fixation of the same SLE sera 
or a normal control serum when added to 300 ug/ml of 
anti-F(ab')2 antibody purified from RA serum RI. 
c. . . .Sera PS, BJ, DW, and PC fixed no additional 
complement when added to 300 ug/ml of RA 
anti-F(ab')2 antibody. 
Note: DW, AS, MH, DH, BJ, and PS represent individual 
SLE patient donors. 
RI represents an RA patient donor. 
PC represents a normal donor. 
Zero percent complement fixed is equivalent to 






































Further, there is a tendency for the sera with higher anti- 
ssDNA activities to fix greater amounts of complement with 
anti-F(ab')2 antibodies than did the sera with lower anti- 
ssDNA activities. The same SLE sera, (Figure IB) when added 
to 300 ug/ml of anti-F(ab')2 antibody purified from RA serum 
fixed significantly smaller amounts of complement (p < 0.01 
by Student's T-test) than was fixed with the same 
concentration of anti-F(ab')2 antibodies purified from SLE 
serum (Figure 1A). Thus, the purified anti-F(ab')2 
antibodies with anti-anti-ssDNA fixed significantly greater 
amounts of complement when combined with SLE sera than did 
purified anti-F(ab')2 antibodies with no anti-anti-ssDNA 
activity. 
Complement fixing ability of ssDNA antigen in SLE sera 
The ability of ssDNA antigen to fix complement when added 
to SLE sera with various anti-ssDNA activities was 
determined in the same manner as was the complement fixing 
ability of the purified anti-F(ab')2 antibodies discussed 
previously. The results are presented in Figure 2. Here, 
the term percent complement fixed is defined as 
[((complement activity present in complement source + serum 
+ PBS) - (complement activity present in complement source + 
serum + ssDNA))/(complement activity present in complement 
source + serum + PBS)] x 100%. The control serum used was 
the same as that used for Figure 1. Also, controls were run 
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in which high concentrations of ssDNA (_>21 ug/ml) were added 
to the complement source without the addition of SLE serum. 
In none of these control runs was more than 10% of the total 
complement activity fixed. 
As shown in Figure 2, ssDNA fixed complement when 
combined with SLE sera previously shown to have various 
anti-ssDNA activities. There was a tendency for the sera 
with higher anti-ssDNA activities to fix greater amounts of 
complement with ssDNA than did the sera with lower anti- 
ssDNA activities. A comparison of Figures 1A and 2 shows 
that ssDNA (5.5 ug/ml), when combined with SLE sera, fixed 
significantly greater amounts of complement (p < 0.05 by 
Student's T-test) than did comparable amounts (6.25 ug/ml) 
of purified SLE anti-F(ab')2 antibody when combined with the 




The percent complement fixation of various SLE sera or a 
normal control serum when added to various concentrations 
of ssDNA. 
a....Figures in parentheses indicate anti-ssDNA antibody 
activity (% binding to 34 ng of 125I-ssDNA) of the 
various sera. 
Note: DW, AS, MH, DH, BJ, and PS represent individual SLE 
patient donors. 
PC represents a normal donor. 
Zero percent complement fixed is equivalent to 
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It has recently been demonstrated that anti-F(ab')2 
(anti-idiotypic) antibodies are present in the serum of 
patients with certain autoimmune diseases and in normal 
individuals (5, 24-27). Furthermore it has been 
demonstrated that such anti-idiotypic antibodies may 
participate in in vivo immune complex formation (5, 29-31). 
In this study, we have shown that purified anti-F(ab')2 
antibodies with anti-anti-ssDNA activity fixed complement 
when combined with autologous or homologous SLE sera (Figure 
IA) . Comparable amounts of anti-F(ab')2 antibodies with no 
anti-anti-ssDNA activity fixed significantly smaller amounts 
of complement when combined with the same SLE sera (Figure 
IB) . Furthermore, ssDNA, when added to the same SLE sera, 
fixed significantly greater amounts of complement than did 
comparable amounts of purified anti-F(ab')2 with anti-anti- 
ssDNA activities (Figures 1A and 2). 
We have previously pointed out that there was a tendency 
for higher ssDNA binding SLE sera to fix greater amounts of 
complement than lower ssDNA binding sera, when added to 
either SLE anti-F(ab')2 or ssDNA. It is evident, from 
Figures 1A and 2, that serum from patient donor PS did not 




for anti-ssDNA, anti-ribonucleoprotein (anti-RNP) antibodies 
and normal C3 levels. Previous investigations (15) have 
demonstrated that the presence of anti-RNP antibodies in 
patients with SLE is associated with milder forms of 
nephritis. Thus, we may speculate, that anti-RNP, via some 
unknown mechanism, may interfere with DNA binding and/or 
complement fixation activity. 
A second possibility for the seemingly aberrant behavior 
of serum PS may involve normal variations of the complement 
fixing ability of anti-DNA antibodies not directly related 
to the absolute quantity of anti-DNA present (19). 
Such heterogeneity in the complement fixing activity of 
anti-ssDNA may reflect variations in IgG subclass 
concentrations of this antibody from serum to serum. 
Likewise, heterogeneity in the complement fixing activity of 
anti-F(ab')2 antibodies may reflect variations in the 
relative concentrations of "private" or autologous anti- 
F(ab')2 and cross-reactive or homologous anti-F(ab')2 
antibodies. That is, the differences in the complement 
fixing activities of the anti-F(ab')2 antibodies may be 
attributable to the concentrations, avidities and cross¬ 
reactivities of the antibodies in the original sera which 
were absorbed and then eluted from the relatively small 
amounts of anti-ssDNA antibodies in normal human F(ab')2 
used for purification. We have obtained some further data 
which suggests these possibilities. Figure 3 demonstrates 
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that SLE serum DW, when added to autologous anti-F(ab')2 
antibodies, fixed substantially greater amounts of 
complement than the same serum added to homologous SLE anti- 
F(ab')2 antibodies. It has been demonstrated that there is 
normal variation in the complement fixing activity of anti- 
DNA antibodies when added to DNA (19). Our data suggests 
that there is also normal variation in the complement fixing 
activity of anti-ssDNA antibodies when added to anti-F(ab')2 
antibodies with anti-anti-ssDNA activity. 
These observations may provide insight into the 
pathogenesis of lupus nephritis. It is well known that the 
complement fixing activity of circulating immune complexes 
is associated with hypocomplementemia and tissue destruction 
(2, 8, 10, 19, 39, 40). Therefore, it is possible that the 
interaction of idiotype with anti-idiotype occurring within 
immune complexes simply fixes complement in addition to that 
fixed by the binding of antigen with antibody. This may 
directly result in increased tissue destruction by 
complement and represent the mechanism by which idiotypic 
interactions could be involved in the pathogenesis of 
glomerular disease as suggested by Goldman and colleagues 
(30-31). On the other hand, complement may solubilize the 
immune complexes (41-43) and perhaps alter their 
pathogenicity (44). Preliminary data from our laboratory 
has suggested, via a polyethylene glycol (PEG) precipitation 




The percent complement fixation of SLE serum DW or normal 
control serum PC when added to various concentrations of 
autologous1 (0--0) or homologous2 (•--&) purified 
anti-F(ab')2 antibodies. 
1 .... Purified from SLE serum from patient donor DW. 
2....Purified from SLE serum from patient donor RL. 
Note: Zero percent complement fixed is equivalent to 
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sera with complement present may reduce the size of immune 
complexes. What effect this might have on the pathogenicity 
of these immune complexes requires future clarification. An 
additional possibility for the role of anti-idiotypic 
antibodies may involve an ability to block antigen-antibody 
binding (25) without fixing complement. That is, perhaps 
concentrations of anti-idiotype which are too low to fix 
complement with idiotype (antibody) can yet interfere with 
antigen-antibody binding. This concept is in accordance 
with Jerne's network theory of auto-regulation by anti- 
idiotypic antibodies (6) and with the experimental work 
provided by many investigators including Abdou et. al. (5) 
and Hahn and colleagues (23, 28). It remains to be seen 
precisely in what way complement fixation by anti-idiotypic 
antibodies plays a role in immunoregulation via the network 
system of antibodies and lymphocytes. 
In this study we have provided evidence that purified 
anti-F(ab')2 antibodies with anti-anti-ssDNA activity fix 
complement when added to SLE sera with anti-ssDNA binding 
activity. A logical extension of this work would involve 
adding anti-F(ab')2 antibodies together with ssDNA to SLE 
sera. Such a system would test the ability of anti-F(ab')2 
antibodies to inhibit or augment complement fixation by 
ssDNA when added to SLE sera. One could speculate that, by 
blocking antigen-antibody binding, anti-F(ab')2 antibodies 
may in fact reduce complement fixation by ssDNA-anti-ssDNA 
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immune complexes. It would also be extremely valuable to 
run the complement fixation assays with purified anti-ssDNA 
and anti-anti-ssDNA antibodies. This would eliminate the 
influence of any possible cross-reacting idiotypes and 
provide further evidence that the complement fixation is 
indeed specifically related to the binding of anti-F(ab')2 
antibodies to anti-ssDNA. At the time the current research 
was carried out purified antibodies were available but in 
insufficient quantity. Such a problem could easily be 
overcome in the future by careful planning. Other 
possibilities for future work include obtaining further data 
on the variations in size of the immune complexes with 
complement fixation and a comparison study of the complement 
fixing ability of anti-idiotype with idiotype versus the 
ability of anti-idiotype to block antigen-antibody binding. 
An inverse correlation in the latter study may have positive 
implications for any possible therapeutic role for anti- 
idiotypic antibodies (23). 
Thus, for the findings in this study to be clinically 
significant, further investigations into the nature of the 
complement fixing ability of antigen, antibody and auto- 
anti-idiotypic antibody complexes are needed. 
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